Tenax Therapeutics, Inc. (“Tenax” or the “Company”) (NASDAQ: TENX) is the subject of a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired the Company’s securities from November 13, 2023 through August 7, 2026, inclusive. The Law Offices of Howard G. Smith today reported the lawsuit, Katz v. Tenax Therapeutics, Inc. et al., which was filed on October 26, 2026 in the U.S. District Court North Carolina Middle District (Case No. 1:26-cv-01264). The deadline for Tenax Therapeutics, Inc. investors to file a lead plaintiff motion is December 28, 2026.
Investors with losses on Tenax Therapeutics, Inc. securities can contact The Law Offices of Howard G. Smith about the Tenax Therapeutics, Inc. class action to discuss potential claims under the federal securities laws before the December 28, 2026 lead plaintiff deadline.
Important dates in the Tenax Therapeutics, Inc. case
- Complaint filing date: October 26, 2026
- Court: U.S. District Court North Carolina Middle District
- Class period: November 13, 2023 through August 7, 2026, inclusive
- Deadline for lead plaintiff motions: December 28, 2026
What happened?
On August 10, 2026, Tenax issued a press release reporting topline results from its Phase 3 LEVEL clinical trial. The press release stated that TNX-103 “did not meet its primary endpoint of improvement in the 6-minute walk distance versus placebo, or the key secondary endpoint of improvement in Kansas City Cardiomyopathy Questionnaire total symptom score.”
On this news, Tenax’s stock fell $12.06 per share, or 89.77%, to close at $1.38 per share on August 10, 2026, thereby injuring investors.
Allegations in the Tenax Therapeutics, Inc. lawsuit
The Tenax Therapeutics, Inc. shareholder lawsuit alleges that, throughout the class period, defendants made materially false and/or misleading statements and failed to disclose material adverse facts about Tenax Therapeutics, Inc.’s business, operations, and prospects. Specifically, the complaint alleges defendants failed to disclose to investors that: (1) TNX-103 was less effective than Defendants had led investors to believe; (2) accordingly, TNX-103’s overall clinical, regulatory, and commercial prospects were overstated; and (3) as a result, defendants’ positive statements about Tenax Therapeutics, Inc.’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Tenax Therapeutics, Inc. investors who purchased or otherwise acquired securities during the class period may move the Court by December 28, 2026 to seek appointment as lead plaintiff in this putative class action.
“The lawsuit against Tenax Therapeutics, Inc. alleges that, among other things, the Company failed to tell investors that TNX-103 was less effective than Defendants had led investors to believe. Tenax Therapeutics, Inc. investors who bought during the class period may be able to pursue their losses through this class action, and the December 28, 2026 lead plaintiff deadline is an important first date,” said Howard G. Smith of The Law Offices of Howard G. Smith.
Next steps for Tenax Therapeutics, Inc. investors
Tenax Therapeutics, Inc. investors who suffered losses may contact The Law Offices of Howard G. Smith to learn about pursuing their claims. For more information, visit the firm’s website, email howardsmith@howardsmithlaw.com, or call (215) 638-4847.
To be a member of the Tenax Therapeutics, Inc. class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent class member. No class has been certified so far in the Tenax Therapeutics, Inc. case.
Common questions from Tenax Therapeutics, Inc. investors
Who is eligible? Investors who acquired Tenax Therapeutics, Inc. securities from November 13, 2023 through August 7, 2026 and suffered losses may qualify for the class in the Tenax Therapeutics, Inc. shareholder lawsuit.
Where is the Tenax Therapeutics, Inc. case pending? The Tenax Therapeutics, Inc. class action, Katz v. Tenax Therapeutics, Inc. et al., is pending in the U.S. District Court North Carolina Middle District (Case No. 1:26-cv-01264).
Do I have to do anything to be in the Tenax Therapeutics, Inc. class? No, Tenax Therapeutics, Inc. investors need not take any action at this time and may remain absent class members.
Does it cost anything? The Law Offices of Howard G. Smith works on contingency, meaning Tenax Therapeutics, Inc. investors owe no attorneys’ fees out of pocket. Any attorneys’ fees and litigation expenses are paid solely from a recovery, if achieved, and require court approval.
About The Law Offices of Howard G. Smith
The Law Offices of Howard G. Smith has helped injured investors recover their money for more than 15 years. The firm prosecutes securities fraud, takeover, and derivative litigation against public companies and their officers, directors, and advisors in federal and state courts nationwide, and has helped clients recover hundreds of millions of dollars in losses. Clients speak directly with a lawyer, who will promptly answer any question.
Prior results do not guarantee a similar outcome.
Related links
- Tenax Therapeutics, Inc. case page, The Law Offices of Howard G. Smith
- Complaint: Katz v. Tenax Therapeutics, Inc. et al., U.S. District Court North Carolina Middle District
- Tenax Press Release
- Tenax Therapeutics, Inc. SEC filings index, EDGAR
- The Law Offices of Howard G. Smith
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261103726994/en/
Media gallery
